A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment
PHASE1CompletedINTERVENTIONAL
Enrollment
16
Participants
Timeline
Start Date
June 12, 2023
Primary Completion Date
June 12, 2024
Study Completion Date
June 12, 2024
Conditions
Renal Impairment
Interventions
DRUG
IXP
Tablets for oral administration.
Trial Locations (2)
33603
Genesis Clinical Research, Tampa
34471
GCP Research, Ocala
All Listed Sponsors
lead
Vertex Pharmaceuticals Incorporated
INDUSTRY
NCT05865171 - A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment | Biotech Hunter | Biotech Hunter